AVXL
Income statement / Annual
Last year (2025), Anavex Life Sciences Corporation's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Anavex Life Sciences Corporation's net income was -$46.38 M.
See Anavex Life Sciences Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
09/30/2025 |
09/30/2024 |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$37.59 M
|
$41.84 M
|
$43.72 M
|
$37.92 M
|
$32.98 M
|
$25.23 M
|
$22.26 M
|
$13.34 M
|
$10.67 M
|
$7.25 M
|
| General & Administrative Expenses |
$13.82 M
|
$11.04 M
|
$12.05 M
|
$13.07 M
|
$9.02 M
|
$5.86 M
|
$6.85 M
|
$5.99 M
|
$5.01 M
|
$8.33 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.82 M
|
$11.04 M
|
$12.05 M
|
$13.07 M
|
$9.02 M
|
$5.86 M
|
$6.85 M
|
$5.99 M
|
$5.01 M
|
$8.33 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$4.38 M
|
$2.47 M
|
$1.63 M
|
$2.02 M
|
$151.40 K
|
| Operating Expenses |
$51.41 M
|
$52.88 M
|
$55.76 M
|
$50.99 M
|
$42.00 M
|
$30.94 M
|
$28.81 M
|
$19.18 M
|
$15.54 M
|
$14.88 M
|
| Cost And Expenses |
$51.41 M
|
$52.88 M
|
$55.76 M
|
$50.99 M
|
$42.00 M
|
$30.94 M
|
$28.81 M
|
$19.18 M
|
$15.54 M
|
$14.88 M
|
| Interest Income |
$4.68 M
|
$7.32 M
|
$6.52 M
|
$947.00 K
|
$26.00 K
|
$179.97 K
|
$207.28 K
|
$255.09 K
|
$88.10 K
|
$11.32 K
|
| Interest Expense |
$0.00
|
$0.00
|
$964.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.25 K
|
| EBITDA |
-$46.38 M |
-$43.00 M |
-$46.54 M |
-$47.62 M |
-$37.64 M |
-$31.06 M |
-$28.88 M |
-$19.13 M |
-$15.57 M |
-$15.04 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$5.03 M
|
$9.88 M
|
$8.26 M
|
$3.37 M
|
$4.36 M
|
$4.50 M
|
$2.54 M
|
$1.58 M
|
$2.05 M
|
$164.16 K
|
| Income Before Tax |
-$46.38 M
|
-$43.00 M
|
-$47.51 M
|
-$47.62 M
|
-$37.64 M
|
-$26.26 M
|
-$26.21 M
|
-$17.38 M
|
-$13.40 M
|
-$14.71 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$358.00 K
|
$268.00 K
|
$22.66 K
|
$82.18 K
|
$72.75 K
|
$59.61 K
|
$29.62 K
|
| Net Income |
-$46.38 M
|
-$43.00 M
|
-$47.51 M
|
-$47.98 M
|
-$37.91 M
|
-$26.28 M
|
-$26.29 M
|
-$17.45 M
|
-$13.46 M
|
-$14.74 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.54 |
-0.52 |
-0.6 |
-0.62 |
-0.54 |
-0.45 |
-0.54 |
-0.39 |
-0.33 |
-0.42 |
| EPS Diluted |
-0.54 |
-0.52 |
-0.6 |
-0.62 |
-0.54 |
-0.45 |
-0.54 |
-0.39 |
-0.33 |
-0.42 |
| Weighted Average Shares Out |
$85.29 M
|
$83.47 M
|
$79.79 M
|
$76.91 M
|
$69.80 M
|
$58.20 M
|
$48.91 M
|
$44.66 M
|
$40.84 M
|
$35.15 M
|
| Weighted Average Shares Out Diluted |
$85.29 M
|
$83.47 M
|
$79.79 M
|
$76.91 M
|
$69.80 M
|
$58.20 M
|
$48.91 M
|
$44.66 M
|
$40.84 M
|
$35.15 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
